Oncoinvent announces publication of normal tissue dosimetry results in Journal of Nuclear Medicine

Contributed by: PR Newswire

Tags

ONCOINVENT-Dosimetry

More Like This

Oncoinvent Reports Positive Final Data from Phase 1 Trial of Radspherin® to Treat Ovarian Cancer

Oncoinvent Announces Positive Final Data from Phase 1/2a Trial of Radspherin® in Patients with Colorectal Peritoneal Metastases

Oncoinvent Announces First Patient Dosed in its Phase 2 Clinical Trial of Radspherin® in Ovarian Cancer Patients

Oncoinvent Reports updated 18-Month Data from Phase 1 Ovarian Cancer Trial with Radspherin®: No new recurrences Demonstrate Continued Promise of Preventing Disease Progression

Oncoinvent achieves 50% recruitment milestone in Phase 2 ovarian cancer study of Radspherin®

Oncoinvent ASA half-yearly report: Strong focus on financial discipline and advancing Phase 2 program in ovarian cancer

Oncoinvent ASA: Second half 2025 results

Oncoinvent ASA: Invitation to Presentation of Q1 2025 company update